Jinhushen Bio completes 67% acquisition with Tianjin Pharma, S shares offer price revised

Felicia Tan
Felicia Tan3/27/2021 12:57 AM GMT+08  • 2 min read
Jinhushen Bio completes 67% acquisition with Tianjin Pharma, S shares offer price revised
The S shares offer price is revised from 89.3 US cents ($1.20) to 89.4 US cents due to a computation mistake.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Tianjin Zhong Xin Pharmaceutical Group says Jinhushen Biological Medical Science and Technology has completed its acquisition in its controlling shareholder, Tianjin Pharmaceutical Holdings (TPH) on March 26.

Jinhushen, on Dec 19, 2020, entered into a sale and purchase agreement (SPA) with Tianjin Bohai State-owned Assets to acquire a 67% stake in TPH.

Further to the completion of the acquisition, Tianjin Pharmaceutical will be making the S shares chain offer according to rule 14.1 of the code.

×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.